Mitapivat, an oral allosteric pyruvate kinase activator, stabilizes and increases the activity of pyruvate kinase, thereby leading to increased intracellular red cell adenosine triphosphate (ATP), resulting in an improvement in anemia and patient-reported outcomes and a reduction in hemolysis. Abbreviation: ADP, adenosine diphosphate.